{"disease":{"id":"adjuvant-therapy","name":"adjuvant therapy"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Postoperative adjuvant therapy for urothelial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Levodopa Adjuvant Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"adjuvant-letrozole-postmenopausal-women","indication_name":"Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adjuvant letrozole (postmenopausal women)","generic_name":"adjuvant-letrozole-postmenopausal-women","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"aromatase","drug_class":"aromatase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03958435","title":"Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07203690","title":"Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07521397","title":"Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.","phase":"","overall_status":"COMPLETED","enrollment_count":5358,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05906407","title":"COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT07019363","title":"CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1903,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06663852","title":"ML Decision Model for G-NEC Adjuvant Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1505,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT03199989","title":"Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1254,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07005557","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1244,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03448549","title":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1191,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05617469","title":"DLCS for Predicting Neoadjuvant Chemotherapy Response","phase":"","overall_status":"UNKNOWN","enrollment_count":1100,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT06385912","title":"Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1090,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03437837","title":"Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China","phase":"","overall_status":"COMPLETED","enrollment_count":1077,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05310318","title":"Prognosis of Low-grade Endometrial Stromal Sarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07417800","title":"Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06149884","title":"Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":978,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT04717947","title":"Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)","phase":"","overall_status":"UNKNOWN","enrollment_count":911,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT05953181","title":"Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":776,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07180693","title":"Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT06755567","title":"Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06925243","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":682,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT06949033","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":668,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT03748485","title":"Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT05524389","title":"Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":624,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06461936","title":"Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":620,"lead_sponsor_name":"Chen Xiaoping","has_results":false},{"nct_id":"NCT03493880","title":"The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03900871","title":"Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT04004559","title":"MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06689462","title":"Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT06405295","title":"Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06671431","title":"Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06041776","title":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":570,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04922853","title":"Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":554,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06909643","title":"Development and Prospective Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04486495","title":"Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":549,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06926179","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06908291","title":"Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03592004","title":"Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT06734702","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06497660","title":"Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":496,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT07051083","title":"Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","phase":"","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06326619","title":"Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"Medizinische Hochschule Brandenburg Theodor Fontane","has_results":false},{"nct_id":"NCT05587296","title":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":474,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT06120309","title":"New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":465,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06704945","title":"No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06630481","title":"Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade","phase":"","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03177382","title":"Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":458,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06288373","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07113275","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":435,"lead_sponsor_name":"Tao Zhang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}